Of note, KRAS amplification and emergence of KRASG12C in cell free DNA have been detected in D/T combination-resistant colon cancer patients, albeit at a much lower frequency than in BRAFi monotherapy [38,44], which suggests that trametinib cannot completely suppress the emergence of MEK/ERK-dependent therapy resistance in cancers. This evidence concerns the gene MAP2K7 and cancer.